Outcome parameters for the recipients at each measurement time point
| Variable | Baseline | 3 months after LDLLT | 12 months after LDLLT |
| BMI kg·m−2 | 18.5±3.3 (12.2–25.2) | 17.8±3.2 (12.0–23.3)* | 19.3±3.6 (12.0–25.5)## |
| VC % predicted | 44.6±17.2 (16.9–88.0) | 54.0±16.8 (26.3–84.7)* | 57.8±19.7 (15.6–101.0)** |
| DLCO % predicted | 24.1±14.5 (7.3–63.2) | 48.4±12.9 (17.5–69.3)** | 48.1±14.2 (23.7–84.6)** |
| Steroid use | 22 (63%) | 34 (97%) | 34 (97%) |
| Average steroid dose mg·kg−1·day−1 | 0.18±0.19 (0–0.78) | 0.38±0.08 (0–0.45) | 0.20±0.12 (0–0.65) |
| Cumulative steroid dose mg·kg−1 | – | 61.6±9.1 (39.0–82.7) | 149.6±26.5 (52.0–215.8) |
| CLAD | – | – | 2 (6%) |
Data are presented as mean±sd deviation (range) or n (%). LDLLT: living-donor lobar lung transplantation; BMI: body mass index; VC: vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CLAD: chronic lung allograft dysfunction. *: p<0.05 compared to baseline; **: p<0.01 compared to baseline; ##: p<0.01 compared to 3 months after LDLLT.